The Government and Pharmaceutical Innovation: Looking Back and Looking Ahead

Author:

Sampat Bhaven N.

Abstract

AbstractCurrent debates about the roles of the public and private sectors in pharmaceutical innovation have a long history. The extent to which, and ways in which, the public sector supports drug innovation has implications for assessments of the returns to public research funding, taxpayer rights in drugs, the argument the high prices are needed to support drug innovation, and the desirability of patenting publicly funded research.

Publisher

Cambridge University Press (CUP)

Subject

Health Policy,General Medicine,Issues, ethics and legal aspects

Reference62 articles.

1. Academic research and industrial innovation

2. 57. The Bayh-Dole 40 Coalition, available at (last visited December 18, 2020).

3. The Drug Industry and Medical Research: The Economics of the Kefauver Committee Investigations

4. 30. Scott, D. , “How a Democratic president could reduce drug prices without Congress”, Vox, available at (last visited December 18, 2020).

5. 33. In principal, the federal iEdison database ought to provide a full listing of all patents resulting from federal grants. The NIH is the only agency that provides iEdison patent data publicly, through its RePORTER system, available at (last visited December 18, 2020), but its listings appear to be incomplete. RePORTER notes “Patent information in RePORTER is incomplete. The patents in RePORTER come from the iEdison database. Not all recipients of NIH funding are compliant with the iEdison reporting requirements, particularly after their NIH support has ended.” Compliance appears to have improved over time, at least if we use RePORTER to gauge accuracy of government interest statements and vice versa. (In principle, the two sources should completely overlap.) However, we don’t know what patents were not reported in either source. A. K. Rai and B. N. Sampat, “Accountability in Patenting of Federally Funded Research”, Nature Biotechnology 30, no. 10 (2012): 953-956.

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3